Hansa Medical: Taking charge of medical affairsHansa Medical, Lund-based developer of novel immunomodulatory enzymes, has recruited Sam Agus as Chief Medical Officer. Agus joins from H. Lundbeck AS, where he was Chief Specialist, Medical Affairs … more ➔
Crescendo Biologics: Aid for late-stage developmentCambridge-based immuno-oncology developer Crescendo Biologics had named Philip Bland-Ward as its Chief Scientific Officer. He joins Crescendo from Kymab where he was responsible for leading its most … more ➔
EFPIA: Engaging for pharma innovationIn April, Nathalie Moll has taken on her new job as Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Moll is also Secretary General of Europe’s largest … more ➔
Endomag: Going beyond the horizonsCancer healthcare company Endomag, founded in 2007 as a spin-out from the University College London (UCL) and the University of Houston, has appointed Peter Keen as non-executive director. Keen will … more ➔
Dentons: All about taxes?? Dentons has announced the cooptation of Julien Le Guyader as partner in the Life Sciences Group of the Paris Office. Le Guyader has been a part of ?? Dentons since 2014. more ➔
Asit biotech: Expertise in vaccinesBelgian clinical-stage immunotherapy developer Asit biotech has appointed Gerd Zettlmeissl as its new Chairman of the Board. Zettlmeissl has been independent director of the company since 2011 … more ➔
Nanobiotix: Oncology expertThe nanomedicine specialist Nanobiotix announced ex-Novartis industry veteran Alain Dostie as new Chief Operating Officer. more ➔
Galapagos: To the clinicMechelen-based biotech Galapagos NV has appointed Walid Abi-Saab to the role of Chief Medical Officer. more ➔
Pharmalink: Global chairSpecialty pharma company Pharmalink AB has elected Maria Carell as Chair of the Board of Directors. Carell replaces Hilde Furberg, who will take over as Vice Chair. more ➔
Oryzon Genomics: Alzheimer aidBarcelona-based epigenetics specialist Oryzon Genomics has made new additions to its Scientific Advisory Board in order to be prepared for the completion of its Phase I trial for dementia drug ORY-2001. … more ➔
